Halozyme director to sell $3.6M in shares

HALOZYME THERAPEUTICS, INC.

Available on EDGAR 09/16/2026 - 04:41 PM EDT Accepted by SEC EDGAR 09/16/2026 - 04:41 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

HALOZYME THERAPEUTICS, INC. (HALO) reports that director Matthew Posard has filed a notice to sell 34,226 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC. The shares were acquired via vesting of restricted stock units between June 5, 2015 and May 5, 2022.

The notice lists an aggregate market value of $3,636,512.50 for the shares to be sold and indicates that there are 113,498,000 shares of common stock outstanding.

Key Figures

Shares to be sold: 34,226 shares Aggregate market value of shares to be sold: $3,636,512.50 Shares outstanding: 113,498,000 shares +2 more

5 metrics

Shares to be sold 34,226 shares Common stock proposed to be sold by Matthew Posard under Rule 144

Aggregate market value of shares to be sold $3,636,512.50 Value reported for the 34,226 Halozyme common shares in the notice

Shares outstanding 113,498,000 shares Halozyme common shares outstanding as listed in the Form 144

Acquisition start date of RSU shares June 5, 2015 Beginning of vesting period for restricted stock units that generated the shares

Acquisition end date of RSU shares May 5, 2022 End of vesting period for restricted stock units that generated the shares

Key Terms

Rule 144, Restricted Stock Units, aggregate market value, Common

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"34226 | 3636512.50 | 113498000"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Common financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for HALO?

The filing discloses that director Matthew Posard intends to sell 34,226 shares of Halozyme common stock under Rule 144, through Morgan Stanley Smith Barney LLC, from shares acquired upon vesting of restricted stock units between 2015 and 2022.

How many HALO shares are covered by Matthew Posard’s Form 144?

The notice covers the proposed sale of 34,226 shares of Halozyme Therapeutics, Inc. common stock. These shares are listed as having been acquired through the vesting of restricted stock units over the period from June 5, 2015 to May 5, 2022.

What is the aggregate market value of the HALO shares in this Form 144?

The Form 144 lists an aggregate market value of $3,636,512.50 for the 34,226 shares of Halozyme common stock proposed to be sold. This figure is reported in the securities information section of the notice.

How many Halozyme (HALO) shares are outstanding according to the Form 144?

The notice states that there are 113,498,000 shares of Halozyme Therapeutics, Inc. common stock outstanding. This number is provided in the securities information section as context for the proposed sale.

What type of securities is Matthew Posard selling in the HALO Form 144?

The Form 144 indicates that the securities are common stock of Halozyme Therapeutics, Inc., originally acquired as Restricted Stock Units granted by the issuer and later converted into shares upon vesting between 2015 and 2022.

Which broker is involved in the HALO Form 144 sale?

The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, as the broker handling the proposed sale of the 34,226 Halozyme common shares under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001543792
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	HALOZYME THERAPEUTICS INC
SEC File Number	001-32335
Address of Issuer	12390 El Camino Real San Diego CALIFORNIA 92130
Phone	8587948889
Name of Person for Whose Account the Securities are To Be Sold	MATTHEW POSARD
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	34226	3636512.50	113498000	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/05/2015	Restricted Stock Units	Issuer			34226	06/05/2015	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 06/05/2015 through 05/05/2022.
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/15/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Matthew Posard
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)